Holen Sie sich die Stockscreener-App
31.13
0.91%
0.2714
Schlusskurs vom Vortag:
$30.86
Offen:
$30.98
24-Stunden-Volumen:
12.31M
Relative Volume:
4.70
Marktkapitalisierung:
$3.90B
Einnahmen:
$1.24B
Nettoeinkommen (Verlust:
$209.00M
KGV:
18.75
EPS:
1.6605
Netto-Cashflow:
$-94.86M
1W Leistung:
-3.50%
1M Leistung:
-9.95%
6M Leistung:
+34.17%
1J Leistung:
+224.71%
1-Tages-Spanne:
$30.47
$32.18
1-Wochen-Bereich:
$29.40
$35.34
52-Wochen-Spanne:
$8.64
$38.00
Indivior Pharmaceuticals Inc Stock (INDV) Company Profile
Firmenname
Indivior Pharmaceuticals Inc
Sektor
Telefon
804-379-1090
Adresse
10710 MIDLOTHIAN TURNPIKE, NORTH CHESTERFIELD
Compare INDV vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INDV
Indivior Pharmaceuticals Inc
|
31.16 | 3.86B | 1.24B | 209.00M | -94.86M | 1.6605 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.79 | 56.14B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
115.14 | 48.74B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.04 | 44.85B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
28.64 | 34.12B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
537.64 | 23.35B | 3.13B | 1.27B | 1.12B | 26.39 |
Indivior Pharmaceuticals Inc Stock (INDV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-07-22 | Fortgesetzt | Jefferies | Buy |
| 2025-01-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-07-23 | Eingeleitet | Piper Sandler | Overweight |
| 2024-04-03 | Eingeleitet | Craig Hallum | Buy |
| 2023-07-13 | Eingeleitet | Northland Capital | Outperform |
Alle ansehen
Indivior Pharmaceuticals Inc Aktie (INDV) Neueste Nachrichten
Indivior PLC Stock (ISIN: US45580R1068) Drops 6% as $450M Convertible Notes Offering Signals Capital - AD HOC NEWS
Indivior Prices Upsized Convertible Notes for Debt Refinancing - TipRanks
Indivior (INDV) Upsizes Convertible Notes Offering to $450M - GuruFocus
Indivior Pharmaceuticals prices upsized $450M convertible senior notes - MSN
Indivior plans $400 million convertible notes offering By Investing.com - Investing.com India
Indivior (INDV) Plans $400 Million Convertible Notes Offering - GuruFocus
Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering - The Manila Times
Indivior prices $450 million convertible notes offering - Investing.com
Indivior Pharmaceuticals Announces Pricing of $450 Million Convertible Senior Notes Offering - Quiver Quantitative
Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering - GlobeNewswire Inc.
Indivior plans $400 million convertible notes offering - Investing.com Nigeria
Indivior proposes $400M convertible senior notes due 2031 to refinance debt, fund buybacks - TradingView
Indivior plans $400M convertible senior notes offering - MSN
Indivior Announces $400 Million Convertible Notes and Buyback - TipRanks
Indivior stock falls after convertible notes offering announced - Investing.com
Indivior Announces Proposed Convertible Senior Notes Offering - Yahoo Finance UK
Opioid Use Disorder Market Booming with Rapid Growth Through 2033 | Indivior PLC • Alkermes • Orexo AB - openPR.com
Indivior (NASDAQ:INDV) Director Stuart Kingsley Buys 940 Shares - MarketBeat
Indivior director Kingsley buys $29,953 in shares - Investing.com
Insider Buying: Barbara Ryan Acquires Shares of Indivior Pharmac - GuruFocus
Indivior (INDV) Study: Sublocade Reduces Healthcare Costs for OU - GuruFocus
New Study Shows Adherence to Monthly Injectable - GlobeNewswire
Ryan Barbara buys Indivior (INDV) shares worth $1,009 - Investing.com South Africa
Victory Capital Management Inc. Makes New $19.44 Million Investment in Indivior PLC $INDV - MarketBeat
Assessing Indivior Pharmaceuticals (NasdaqGS:INDV) Valuation After Earnings Growth And New US$400 Million Buyback - Sahm
Claret Asset Management Corp Has $18.92 Million Stake in Indivior PLC $INDV - MarketBeat
Implied Volatility Spikes for Indivior Pharmaceuticals Equity Options - Bitget
Implied Volatility Surging for Indivior Pharmaceuticals Stock Options - TradingView
Jefferies Financial Group Inc. Has $17.05 Million Stock Holdings in Indivior PLC $INDV - MarketBeat
How Strong Q4 Results, Reaffirmed 2026 Outlook and New Buyback At Indivior (INDV) Has Changed Its Investment Story - Sahm
Indivior (INDV) Q4 2025 Earnings Call Transcript - AOL.com
Is It Time To Reassess Indivior Pharmaceuticals (INDV) After Its Recent Pullback In Price? - simplywall.st
Vanguard Group Inc. Has $83.10 Million Holdings in Indivior PLC $INDV - MarketBeat
Global Transdermal Skin Patch Market Size, Growth, Trends & - openPR.com
Royce & Associates LP Buys Shares of 246,524 Indivior PLC $INDV - MarketBeat
Indivior PLC (NASDAQ:INDV) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Indivior Pharmaceuticals, Inc. (INDV): Investor Outlook With 45% Potential Upside - DirectorsTalk Interviews
Quantbot Technologies LP Makes New Investment in Indivior PLC $INDV - MarketBeat
Equities Analysts Issue Forecasts for Indivior Q4 Earnings - MarketBeat
HC Wainwright Issues Negative Forecast for Indivior Earnings - MarketBeat
Indivior Pharmaceuticals (INDV) Valuation Check After Strong Long Term Shareholder Returns - Sahm
Indivior’s Strong 2025 Results and US$400 Million Buyback Might Change The Case For Investing In Indivior Pharmaceuticals (INDV) - simplywall.st
Decoding Indivior Pharmaceuticals Inc (INDV): A Strategic SWOT I - GuruFocus
A Look At Indivior Pharmaceuticals (NasdaqGS:INDV) Valuation After Its Recent Name Change - Yahoo Finance
Indivior Pharmaceuticals, Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Indivior (NASDAQ:INDV) Announces Earnings Results - MarketBeat
INDVIndivior Pharmaceuticals Inc. Latest Stock News & Market Updates - Stock Titan
Indivior Pharmaceuticals Inc. (INDV) Tops Q4 Earnings and Revenue Estimates - Yahoo Finance
Sector Update: Health Care - marketscreener.com
Earnings call transcript: Indivior Q4 2025 beats expectations, stock rises By Investing.com - Investing.com South Africa
Earnings call transcript: Indivior Q4 2025 beats expectations, stock rises - Investing.com Nigeria
Finanzdaten der Indivior Pharmaceuticals Inc-Aktie (INDV)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.00%
1.29%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):